 Connection
Mario Enrico Canonico to Mineralocorticoid Receptor Antagonists
This is a "connection" page, showing publications Mario Enrico Canonico has written about Mineralocorticoid Receptor Antagonists.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.965 |
|
|
|
-
Basile C, Monzo L, Farmakis D, Keramida K, Liori S, Kapelios CJ, Sverdlov AL, Grupper A, Ambrosy AP, Canonico ME. Trials and tribulations of spironolactone in heart failure with preserved ejection fraction: Insights from the SPIRIT-HF trial. Heart Fail Rev. 2026 Aug 31; 31(1).
Score: 0.914
-
Rafei AE, Harrington JA, Tavares CAM, Guimarães PO, Ambrosy AP, Bonaca MP, Sauer AJ, Vardeny O, Canonico ME. Heart failure with preserved ejection fraction therapeutics: in search of the pillars. Heart Fail Rev. 2025 09; 30(5):1005-1014.
Score: 0.837
-
Harrington JL, Canonico ME, El Rafei A, Solomon SD, Teerlink JR, Vaduganathan M, Zieroth SR, Bonaca MP, Sauer AJ. Nonsteroidal and Steroidal Mineralocorticoid Antagonists: Rationale, Evidence, and Unanswered Questions. JACC Heart Fail. 2025 Oct; 13(10):102637.
Score: 0.213
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|